{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23885911",
  "DateCompleted": {
    "Year": "2014",
    "Month": "03",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "30"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.jvir.2013.05.040",
      "S1051-0443(13)01024-5"
    ],
    "Journal": {
      "ISSN": "1535-7732",
      "JournalIssue": {
        "Volume": "24",
        "Issue": "8",
        "PubDate": {
          "Year": "2013",
          "Month": "Aug"
        }
      },
      "Title": "Journal of vascular and interventional radiology : JVIR",
      "ISOAbbreviation": "J Vasc Interv Radiol"
    },
    "ArticleTitle": "Oncolytic virotherapy.",
    "Pagination": {
      "StartPage": "1115",
      "EndPage": "1122",
      "MedlinePgn": "1115-22"
    },
    "Abstract": {
      "AbstractText": [
        "Oncolytic virotherapy is an emerging technology that uses engineered viruses to treat malignancies. Viruses can be designed with biological specificity to infect cancerous cells preferentially, and to replicate in these cells exclusively. Malignant cells may be killed directly by overwhelming viral infection and lysis, which releases additional viral particles to infect neighboring cells and distant metastases. Viral infections may also activate the immune system, unmask stealthy tumor antigens, and aid the immune system to recognize and attack neoplasms. Delivery of live virus particles is potentially complex, and may require the expertise of the interventional community."
      ],
      "CopyrightInformation": "Copyright \u00a9 2013. Published by Elsevier Inc."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Interventional Radiology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA."
          }
        ],
        "LastName": "Sze",
        "ForeName": "Daniel Y",
        "Initials": "DY"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Reid",
        "ForeName": "Tony R",
        "Initials": "TR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rose",
        "ForeName": "Steven C",
        "Initials": "SC"
      }
    ],
    "PublicationTypeList": [
      "Historical Article",
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Vasc Interv Radiol",
    "NlmUniqueID": "9203369",
    "ISSNLinking": "1051-0443"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cytopathogenic Effect, Viral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "History, 20th Century"
    },
    {
      "QualifierName": [],
      "DescriptorName": "History, 21st Century"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host Specificity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "history",
        "pathology",
        "therapy",
        "virology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "adverse effects",
        "history"
      ],
      "DescriptorName": "Oncolytic Virotherapy"
    },
    {
      "QualifierName": [
        "genetics",
        "pathogenicity"
      ],
      "DescriptorName": "Oncolytic Viruses"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Radiography, Interventional"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}